Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Plasma cell 1Gynecologic 1Genitourinary 1

Conditions

Wilms Tumor 1Triple Negative Breast Neoplasms 1Rhabdoid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Castration Levels of Testosterone 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 2Ifosfamide 2Filgrastim 2Doxorubicin 2selinexor 1pembrolizumab 1lorvotuzumab mertansine 1fludarabine phosphate 1fludarabine 1Specimen Handling 1Radiotherapy 1Mesna 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Imatinib Mesylate 1Cyclophosphamide 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibrosarcoma × selinexor × Genitourinary × Clear all
NCT05985161 2026-05-06

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
GenitourinarySarcoma

Wilms Tumor, Neurofibrosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡